z-logo
open-access-imgOpen Access
A case of classic adult pityriasis rubra pilaris successfully treated with a combination of acitretin and ustekinumab: A case report
Author(s) -
Celina DeBiasio,
Janelle Cyr,
Yasmine Ayroud,
Steven J. Glassman
Publication year - 2022
Publication title -
sage open medical case reports
Language(s) - English
Resource type - Journals
ISSN - 2050-313X
DOI - 10.1177/2050313x221093453
Subject(s) - pityriasis rubra pilaris , acitretin , medicine , dermatology , ustekinumab , psoriasis , disease , adalimumab
Classic adult pityriasis rubra pilaris is a severe papulosquamous disease that tends to resolve in 3–5 years but can have a devastating impact on patients while active. It shares features with psoriasis, but treatment remains largely empiric, based on case reports and series. The condition is often refractory to treatment, especially initially, with topical corticosteroids and oral acitretin the more commonly employed agents. Relatively high doses of acitretin are needed for adequate response, and adverse events often limit adherence. Given the similarity to psoriasis, biologic agents approved for psoriasis have been used with good effect in classic adult pityriasis rubra pilaris and show better tolerance than other agents. In this report, we describe the successful use of a combination of acitretin and ustekinumab in a case of classic adult pityriasis rubra pilaris.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here